|
1
|
Horváth G, Hunyady B, Gervain J, Lengyel
G, Makara M, Pár A, Szalay F, Telegdy L and Tornai I: Diagnosis and
treatment of chronic hepatitis B and D. Hungarian National
Consensus Guideline. Orv Hetil. (Suppl 155). 25–36. 2014.[(In
Hungarian)]. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Peng H, Liu J, Yang M, Tong S, Yin W, Tang
H, Hu P, Hu H and Ren H: Efficacy of lamivudine combined with
adefovir dipivoxil versus entecavir monotherapy in patients with
hepatitis B-associated decompensated cirrhosis: a meta-analysis. J
Clin Pharmacol. 54:189–200. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
3
|
Zhang L and Chang Y: Experimental study on
effect of Dahuang Zhechong wan combined with adefovir dipivoxil in
preventing hepatic fibrosis in patients with chronic hepatitis B.
Zhongguo Zhong Yao Za Zhi. 37:862–864. 2012.(In Chinese).
PubMed/NCBI
|
|
4
|
Liu Y, Wang C, Zhong Y, Chen L, Li X, Ji
D, Wang H, Xin S, Zoulim F and Xu D: Evolution and suppression of
HBV strains with multidrug resistance to lamivudine, adefovir
dipivoxil and entecavir in a patient with chronic hepatitis B.
Antivir Ther. 15:1185–1190. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zhu D, Liu L, Yang D, Fu S, Bian Y, Sun Z,
He J, Su L, Zhang L, Peng H, et al: Clearing persistent
extracellular antigen of hepatitis B virus: an immunomodulatory
strategy to reverse tolerance for an effective therapeutic
vaccination. J Immunol. 196:3079–3087. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wang GL, Liu Y, Qiu P, Zhou SF, Xu LF, Wen
P, Wen JB and Xiao XZ: Cost-effectiveness of lamivudine,
telbivudine, adefovir dipivoxil and entecavir on decompensated
hepatitis B virus-related cirrhosis. Eur Rev Med Pharmacol Sci.
20:866–872. 2016.PubMed/NCBI
|
|
7
|
Zhou Y, Zhang H and Li Y: IL-35 expression
in peripheral blood CD4(+) T cells from chronic hepatitis B
virus-infected patients directly correlates with virus load.
Cytokine. 73:169–175. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wang XL, Ren JP, Wang XQ, Wang XH, Yang SF
and Xiong Y: Mutations in pre-core and basic core promoter regions
of hepatitis B virus in chronic hepatitis B patients. World J
Gastroenterol. 22:3268–3274. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Heymann F and Tacke F: Immunology in the
liver - from homeostasis to disease. Nat Rev Gastroenterol Hepatol.
13:88–110. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Gummow J, Li Y, Yu W, Garrod T,
Wijesundara D, Brennan AJ, Mullick R, Voskoboinik I, Grubor-Bauk B
and Gowans EJ: A multiantigenic DNA vaccine that induces broad
hepatitis C virus-specific T-cell responses in mice. J Virol.
89:7991–8002. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Chen Y, Huang Z, Ma D, Chen L, Lai Q,
Huang X, Zhou J, Zhang X, Ma Q, Chen Z, et al: Involvement of
soluble scavenger receptor A in suppression of T cell activation in
patients with chronic hepatitis B. BMC Immunol. 16:292015.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Bull RA, Leung P, Gaudieri S, Deshpande P,
Cameron B, Walker M, Chopra A, Lloyd AR and Luciani F:
Transmitted/founder viruses rapidly escape from CD8+ T
cell responses in acute hepatitis C virus infection. J Virol.
89:5478–5490. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yang HC and Kao JH: Viral hepatitis. HBV
cure - can we pin our hopes on immunotherapy? Nat Rev Gastroenterol
Hepatol. 12:129–131. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Koh S and Bertoletti A: Circumventing
failed antiviral immunity in chronic hepatitis B virus infection:
triggering virus-specific or innate-like T cell response? Med
Microbiol Immunol (Berl). 204:87–94. 2015. View Article : Google Scholar
|
|
15
|
Holz L and Rehermann B: T cell responses
in hepatitis C virus infection: historical overview and goals for
future research. Antiviral Res. 114:96–105. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Raziorrouh B, Sacher K, Tawar RG, Emmerich
F, Neumann-Haefelin C, Baumert TF, Thimme R and Boettler T:
Virus-specific CD4+ T cells have functional and
phenotypic characteristics of follicular T-helper cells in patients
with acute and chronic HCV infections. Gastroenterology.
150:696–706. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wang Y, Liu S, Chen YU, Zheng S, Zhou LI,
Hua T, Sui S, Lu F and Duan Z: Evolution of entecavir-resistant
hepatitis B virus during entecavir and adefovir dipivoxil
combination therapy. Exp Ther Med. 11:117–123. 2016.PubMed/NCBI
|
|
18
|
Li X, Jie Y, You X, Shi H, Zhang M, Wu Y,
Lin G, Li X, Gao Z and Chong Y: Optimized combination therapies
with adefovir dipivoxil (ADV) and lamivudine, telbivudine, or
entecavir may be effective for chronic hepatitis B patients with a
suboptimal response to ADV monotherapy. Int J Clin Exp Med.
8:21062–21070. 2015.PubMed/NCBI
|
